Swissmedic authorises a medicinal product under the Marketing Authorisation for Global Health Products (MAGHP) procedure for the first time
Bern, 14.5.2020 - This approval in Switzerland paves the way for the approval and introduction in low- and middle-income countries. For the first time Swissmedic, the Swiss Agency for Therapeutic Products, has authorised a new medicinal product (known as an “API with innovation”) under the MAGHP procedure. Experts from the National Regulatory Authorities (NRAs) of Uganda, Kenya, Tanzania (mainland and Zanzibar), South Sudan, Nigeria, Democratic Republic of Congo and Ethiopia have participated in the procedure.